Journal of
Clinical & Medical Surgery

www.jclinmedsurgery.com

ISSN 2833-5465
Open Access
Volume 6

Research Article

The bladder remembers: Why storage luts persist after successful deobstructive surgery

João Antonio Pereira-Correia*; Igor Boechat Tinoco Martins; Kerohene Layce Bernardes; Daniel De Morais Perpétuo

Department of Urology, Servidores do Estado Federal Hospital, Brazil.

***Corresponding Author:**
João Antonio Pereira-Correia
Department of Urology, Servidores do Estado Federal Hospital, Brazil.
Email: joaoapc@ig.com.br

Article Information

Received: July 31, 2026
Accepted: Aug 10, 2026
Published: Aug 17, 2026
Archived: www.jclinmedsurgery.com

Abstract

Introduction: Prostatic deobstructive surgery (e.g., TURP, HoLEP, ThuLEP) is the gold standard for moderate-to-severe LUTS secondary to Benign Prostatic Obstruction (BPO). While it predictably improves Q_max, PVR, and IPSS, many patients experience persistent, refractory storage symptoms. This dissociation between objective structural relief and subjective symptomatic resolution causes significant postoperative dissatisfaction. In our study, we critically review the key preoperative predictors and pathophysiological mechanisms of this persistent bladder dysfunction, proposing a practical algorithm to optimize postoperative management and patient counseling.

Methods: A comprehensive literature review was performed using PubMed/MEDLINE, focusing primarily on contemporary clinical evidence from the last decade, while incorporating landmark consensus statements and foundational urological terminology studies.

Results: Evidence demonstrates that persistent postoperative storage LUTS is dictated by a multifaceted interplay of preoperative parameters. Key independent predictors include advanced age, severe baseline storage scores, low cystometric capacity, terminal or low-volume Detrusor Overactivity (DO), Detrusor Underactivity (DU), metabolic syndrome, diabetes, and a lower Bladder Outlet Obstruction Index (BOOI). Ischemic, neurogenic, and structural remodeling of the detrusor wall under chronic hydrostatic stress limits its immediate functional reversibility following anatomical relief.

Conclusions: Postoperative storage LUTS persistence reflects an established vesicle-centric or systemic phenotype rather than surgical failure. Preoperative phenotyping utilizing symptom scores, frequency-volume charts, and selective multi-channel urodynamics is critical to optimize patient selection, guide realistic counseling, manage expectations, and formulate individualized care pathways.

Keywords: Prostatic hyperplasia; Transurethral resection of prostate; Urinary bladder; Overactive; Lower urinary tract symptoms.

Citation: Pereira-Correia JA, Tinoco Martins IB, Layce Bernardes K, Morais Perpétuo DD. The bladder remembers: Why storage luts persist after successful deobstructive surgery. J Clin Med Surgery. 2026; 6(2): 1236.

Introduction

Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) represent one of the most pervasive clinical syndromes affecting aging men worldwide, carrying profound socioeconomic costs and heavily compromising health-related quality of life [1]. Historically, the therapeutic paradigm of male LUTS focused narrowly on a prostate-centric model, where mechanical and dynamic obstruction of the bladder outlet by an enlarging gland was viewed as the sole driver of urinary dysfunction [1,2].

However, contemporary urological research has established that male LUTS is a deeply heterogeneous, multi-organ syndrome resulting from a complex, interlaced network involving structural changes in the prostate, intrinsic bladder wall remodeling, peripheral and central neurological alterations, metabolic aberrations, vascular ischemia, and the inescapable physiological impacts of chronological aging [2,3].

Clinically, LUTS is categorized into storage (urgency, frequency, nocturia, urgency incontinence), voiding (hesitancy, weak stream, intermittency, straining), and post-micturition symptoms [3]. For decades, surgical interventions such as monopolar or bipolar Transurethral Resection of the Prostate (TURP) and, more recently, Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP), have stood as the pillars of definitive management [4]. These procedures are highly effective at debulking obstructing tissue, reducing the urethral pressure profile, increasing the maximum flow rate (Q_max), and dramatically emptying the Post-Void Residual (PVR) volume [4,5].

Yet, across all contemporary surgical literature, a persistent clinical reality remains: A significant, reproducible proportion of patients-ranging from 20% to over 45% depending on definitions and follow-up intervals-continue to suffer from debilitating storage symptoms in the months or even years following technically flawless anatomical deobstruction [5,6].

The persistence of storage LUTS-specifically the triad of urgency, high daytime frequency, and nocturia-is frequently interpreted by the patient as a failure of the surgical procedure [6]. This generates deep post-operative frustration, undermines patient-reported outcome measures, and presents a taxing management dilemma for the practicing urologist [6,7]. When objective indices confirm that the outlet is wide open ("BOOI"<20), the persistence of these symptoms highlights a critical truth: the bladder remembers [7]. The detrusor muscle, urothelium, and localized neural networks bear the permanent or slowly reversible scars of long-standing hydrostatic overload [7,8].

This narrative review aims to dissect the structural, urodynamic, metabolic, and clinical predictors of persistent storage LUTS following male deobstructive surgery, offering an evidence-based framework to optimize preoperative counseling, guide selective diagnostic workups, and direct targeted postoperative therapies.

Methods

A comprehensive, non-systematic literature narrative review was structured via the PubMed/MEDLINE database [8]. The search strategy focused primarily on contemporary clinical and mechanical evidence from the last decade to capture modern surgical outcomes, while selectively including landmark consensus guidelines and foundational urological terminology studies to ensure conceptual rigor [3,8]. The keywords and controlled vocabulary (MeSH terms) utilized in various combinations included: lower urinary tract symptoms, benign prostatic obstruction, detrusor overactivity, transurethral resection of the prostate, laser enucleation, and postoperative storage symptoms [6,8].

The selection criteria prioritized high-impact Randomized Controlled Trials (RCTs), large-scale prospective cohort studies, multi-center retrospective analyses, and recent systematic reviews evaluating the functional outcomes and pathophysiological mechanisms of the post-deobstructive urinary bladder [5,8].

Pathophysiological mechanisms: The structural and functional memory of the bladder

To understand why storage symptoms persist after structural resistance is eliminated, one must examine the profound ultra-structural, cellular, and neuro-urological remodeling that the urinary bladder undergoes during chronic Bladder Outlet Obstruction (BOO) [7]. When the prostate pinches the prostatic urethra, the bladder is forced to generate progressively higher intraluminal pressures to overcome the resistance and maintain micturition [8,9]. This hydrostatic stress initiates a highly structured cascade of tissue adaptation, transitioning through compensatory hyperfunctional phases before culminating in decompensation [9].

Cellular hypertrophy, extracellular matrix deposition, and fibrosis

The immediate response of the detrusor smooth muscle cells to elevated afterload is cellular hypertrophy [9]. While this hypertrophy helps preserve voiding function initially, it triggers a pathological gene expression profile [9,10]. Interstitial cells and fibroblasts within the detrusor matrix become activated, leading to a profound dysregulation of Extracellular Matrix (ECM) deposition [10].

Type I and Type III collagen bundles infiltrate the interstitial spaces between smooth muscle fascicles, disrupting the normal spatial orientation of the detrusor fibers [9,10]. This accumulation of rigid connective tissue compromises the passive viscoelastic properties of the bladder wall, resulting in a marked reduction in cystometric compliance and an inherent loss of elasticity during the storage phase [10].

Patchy denervation, ischemia, and microvascular dysfunction

Compounding the structural remodeling is the development of tissue ischemia [11]. During the filling phase, high intramural pressure within a thick, rigid bladder wall compresses intramural microvessels, severely reducing arterial perfusion and causing cyclical, repetitive ischemia-reperfusion injury during micturition cycles [11,12]. This chronic state of low-grade hypoxia leads to mitochondrial damage in smooth muscle cells and efferent nerve endings [12].

Histological evaluations of obstructed animal and human bladders consistently show "patchy denervation" of the detrusor layer [11,12]. To compensate for this localized loss of normal autonomic innervation, the remaining smooth muscle cells display an altered sensitivity to acetylcholine [12]. They develop an exaggerated, coordinated response to minimal neurotransmitter exposure-an anatomical phenomenon termed denervation supersensitivity-which manifests urodynamically as involuntary detrusor contractions (detrusor overactivity) [11,12].

Urothelial and afferent signaling alterations

Modern neuro-urological science has shifted the focus of bladder storage physiology from the detrusor muscle to the urothelium and lamina propria [13]. The urothelium is no longer viewed as a simple impermeable barrier; it functions as a highly sophisticated mechanoreceptor [13,14]. In response to stretching, tissue hypoxia, or mechanical shear stress caused by BOO, urothelial cells release excessive amounts of excitatory neurotransmitters and neuromodulators, most notably Adenosine Triphosphate (ATP) and Nitric Oxide (NO), while downregulating inhibitory signals [14].

These molecules diffuse into the suburothelium, where they bind to specific purinergic (P2X_3) and vanilloid (TRPV_1) receptors located on unmyelinated C-fiber afferent nerves [13,14]. Under normal conditions, these C-fibers are quiescent ("silent nociceptors") [14]. However, chronic chemical stimulation and structural distortion recruit and activate these fibers, lowering the firing threshold of the micturition reflex [13,14]. The brain perceives this altered afferent signaling as early, intense, and uninhibited sensations of urinary urgency, establishing the sensory basis of Overactive Bladder (OAB) symptoms that can persist long after the initial physical obstruction has been surgically resected [14].

Preoperative predictors and clinical phenotypes

Advanced chronological age: Advanced age is one of the most robust and consistently replicated independent risk factors for persistent post-deobstructive storage symptoms [5]. In a seminal prospective cohort analysis, Choi et al. [5] demonstrated that patients over 70 years of age had significantly higher rates of persistent OAB symptoms at 12 months post-TURP compared to younger cohorts. The impact of age is multifactorial, representing a combination of long-standing, uncorrected BOO (a longer duration of tissue damage) and the independent effects of biological aging on the lower urinary tract [2,5].

Senescent bladders demonstrate systemic degenerative modifications, including progressive microvascular atherosclerosis, age-related central nervous system changes that reduce cortical inhibition over the primitive micturition center, and an increase in systemic inflammatory cytokines [2]. Consequently, while elderly men achieve comparable relative improvements in maximum flow rates and voiding efficiency postoperatively, their aging detrusor and neurological pathways possess a significantly lower capacity for functional plasticity and structural reversal [5].

Baseline severity of storage symptoms and OAB phenotypes: The initial clinical presentation provides critical clues regarding the underlying functional state of the bladder [3]. Men whose baseline symptom profile is heavily dominated by storage symptoms-manifesting as severe urgency, regular UUI episodes, and a high storage IPSS sub-score-exhibit significantly higher rates of post-operative failure to achieve complete storage resolution [3,6].

This clinical phenotype indicates that the pathology has shifted from a simple mechanical obstruction to an autonomous bladder disease process [6]. When the storage symptom sub-score dwarfs the voiding sub-score, the bladder has often developed an independent hyperactive state that is no longer directly dependent on structural outlet resistance, rendering it refractory to pure anatomical deobstruction [6,7].

Urodynamic predictors: Capacity, Compliance, and Overactivity.

While standard guidelines do not mandate multi-channel pressure-flow Urodynamic Studies (UDS) for every patient undergoing BPH surgery, UDS remains an invaluable diagnostic tool for uncovering the underlying pathophysiology and providing prognostic parameters [15].

- **Low cystometric bladder capacity and compliance:** A severely reduced Maximum Cystometric Capacity (MCC) during pre-operative filling cystometry is a strong indicator of persistent storage dysfunction [15]. Clinical trials by [15], show that a pre-operative MCC<250 mL, particularly when paired with impaired bladder compliance (less than 15--20 mL/cm H_2O), carries a very high probability of persistent postoperative urgency and frequency. This structural stiffness prevents the bladder from physically expanding to accommodate normal volumes, even after the outlet resistance is reduced [10,15].

- **Detrusor Overactivity (DO) profile:** The presence of preoperative DO is a classic finding in obstructed men, traditionally expected to resolve in 50% to 70% of cases following surgery [15,16]. However, qualitative details of the DO profile during UDS are highly predictive of non-resolution [16]. The consensus statement from the International Consultation on Incontinence-Research Society (ICI-RS) [16] emphasizes that low-volume DO (where involuntary detrusor contractions occur at an early stage of filling, e.g., <150 mL) and high-amplitude terminal DO are highly resistant to surgical cure, reflecting severe neurogenic or myogenic disinhibition.

- **Detrusor Underactivity (DU) and impaired contractility:** In a detailed retrospective analysis of long-term outcomes [17] demonstrated that patients with a low pre-operative Bladder Contractility Index (BCI<100) or significant detrusor underactivity (DU) had a significantly lower probability of resolving post-operative OAB symptoms. A weak, underactive detrusor cannot generate a sustained contraction sufficient to clear the bladder completely, resulting in elevated PVR volumes [17]. This persistent fullness reduces the functional capacity of the bladder, leading to rapid re-filling, severe frequency, and chronic afferent C-fiber activation from concentrated solutes [14,17].

- **The Bladder Outlet Obstruction Index (BOOI):** Counterintuitively, a lower pre-operative BOOI (BOOI=P_det Q_max-2×Q_max) is associated with a higher risk of persistent storage LUTS after surgery [15,17]. Patients with a high BOOI>40 show clear mechanical obstruction; their storage symptoms are secondary to this severe outlet resistance and are highly likely to resolve once the obstruction is surgically relieved [15]. Conversely, patients with low BOOI scores (<20--30) who present with severe storage LUTS often have an intrinsic bladder pathology (e.g., idiopathic OAB, neurogenic bladder) or

systemic comorbidity rather than true mechanical obstruction [15,17] (Table 1).

Systemic comorbidities and multifactorial challenges

Nocturia as an extra-prostatic syndrome: Among all storage symptoms, nocturia stands out as the most complex, disruptive, and resistant to surgical cure [18]. Prospective surgical trials systematically show that nocturia exhibits the lowest resolution rate of all symptoms within the IPSS inventory [5,18].

The poor responsiveness of nocturia to prostatic deobstruction stems from its highly diverse, extra-prostatic etiology [18,19]. Nocturia is highly influenced by systemic clinical conditions, including nocturnal polyuria (excretion of >20% to 33% of the total 24-hour urine volume during sleep), Obstructive Sleep Apnea (OSA), congestive heart failure, chronic kidney disease, poorly timed evening fluid or diuretic intake, and primary sleep disorders [19].

For instance, in patients with OSA, the increased negative intrathoracic pressure generated during apneic episodes stretches the right atrium of the heart, stimulating the secretion of Atrial Natriuretic Peptide (ANP) [19]. ANP promotes rapid renal excretion of sodium and water, causing massive nocturnal polyuria that overwhelms normal bladder storage capacity, regardless of whether the prostate has been resected [18,19]. Utilizing a pre-operative 3-day frequency-volume chart (bladder diary) is an invaluable, evidence-based method to differentiate between a bladder with low nocturnal capacity and systemic nocturnal polyuria [19].

Diabetes Mellitus and Diabetic Cystopathy: Diabetes mellitus is a well-established driver of long-term bladder dysfunction, initiating a progressive pathological process known as diabetic cystopathy [20]. In its early stages, systemic hyperglycemia causes osmotic diuresis, forcing the bladder to manage chronically elevated volumes, which leads to compensatory hypertrophy [20,21]. As the disease advances, chronic hyperglycemia induces the accumulation of Advanced Glycation End-Products (AGEs) within the pelvic tissue, triggering microvascular ischemia and profound autonomic neuropathy [21]. This dual injury damages both the sensory and motor innervation of the bladder [20,21]. Clinically, this manifests as a mixed phenotype: a hypersensitive bladder with poor compliance and spontaneous detrusor contractions during filling, combined with an underactive, poorly contracting detrusor during voiding [21].

Metabolic Syndrome and Pelvic Arterial Atherosclerosis: Metabolic syndrome-the clustering of central obesity, hypertension, dyslipidemia, and insulin resistance-is strongly linked to pelvic arterial atherosclerosis and chronic bladder ischemia [22]. Chronic hypoperfusion of the pelvic organs triggers a localized pro-inflammatory cascade within the bladder wall [22,23]. This ischemia-induced inflammation activates transcription factors like Hypoxia-Inducible Factor 1-alpha ("HIF-1" α) and Nerve Growth Factor (NGF), which upregulate the density and sensitivity of suburothelial sensory afferents [23]. This microvascular and inflammatory remodeling creates a highly sensitive bladder that remains hyperactive even after surgical deobstruction [22,23].

Clinical Framework for Preoperative and Postoperative Management

Preoperative Evaluation and Predictive Models: Multi-variable predictive models and nomograms have been explored to assist clinicians in calculating individual risk profiles [24], explored the utility of the ice water test (a traditional neurological provocative test) to evaluate intrinsic bladder reflexes and developed a clinical nomogram designed to predict the persistence of storage symptoms after TURP based on reflex responsiveness, baseline storage scores, and chronological age.

A recent comprehensive systematic review by [25] evaluated all existing predictive tools for post-deobstructive storage symptoms and concluded that, to date, no single clinical or urodynamic parameter possesses sufficient diagnostic power to serve as a standalone predictor. The future of clinical prediction lies in the integration of multi-variable models that combine patient demographics, standardized symptom questionnaires, functional data, non-invasive diagnostics, and selective invasive urodynamics [25] (Table 2).

Structured postoperative management protocol: When a patient presents with persistent or bothersome storage LUTS 3 to 6 months after deobstructive surgery, a systematic, step-by-step diagnostic and therapeutic protocol must be initiated [6,25]:

Step 1: Exclude anatomic and surgical complications: Rule out persistent urinary tract infections via urinalysis and culture. Perform non-invasive uroflowmetry and PVR measurements. A low Q_max combined with an elevated PVR requires outpatient cystoscopy or retro-urethrography to rule out urethral stricture, bladder neck contracture, or significant residual prostatic tissue [4].

Step 2: Implement first-line conservative and behavioral therapies: Once anatomical patency is confirmed (the outlet is wide open with minimal PVR), eliminate bladder irritants (caffeine, alcohol, spicy foods), regulate fluid intake (restricting fluids for 3-4 hours before bedtime), and institute formal bladder-retraining protocols with timed voiding schedules to gradually rebuild functional capacity [6].

Step 3: Initiate targeted pharmacotherapy:

- Beta-3 Adrenergic Agonists (e.g., Mirabegron, Vibegron): Promote detrusor relaxation during filling without compromising contractility during voiding [26]. Preferred as first-line systemic pharmacotherapy due to their excellent safety profile and minimal risk of urinary retention, particularly in elderly men or those with baseline impaired contractility [17,26].

- Antimuscarinic monotherapy (e.g., Solifenacin, Tolterodine): Suppress involuntary detrusor contractions [26]. Must be used with caution and only initiated if the PVR is reliably <100--150 mL, with strict monitoring during follow-up [6,26].

- Low-Dose Desmopressin: For patients whose frequency-volume charts confirm persistent, isolated nocturnal polyuria refractory to prostatic deobstruction and fluid restriction [19]. Clinicians must strictly monitor serum sodium levels at baseline, day 3, day 7, and monthly during early treatment to prevent hyponatremia, especially in men >65 years of age [19].

Step 4: Consider advanced third-line interventions: In instances where storage symptoms remain completely refractory to combined behavioral modification and maximal medical therapy, the patient should undergo a comprehensive multi-channel urodynamic re-evaluation [15,16]. If persistent,

Table 1: Multidimensional pathophysiological framework of preoperative predictors.

Domain	Preoperative predictor	Pathophysiological mechanism	Clinical impact & phenotypic presentation
Clinical	Advanced Age (>70 years)	Microvascular atherosclerosis; chronic hypoxia; reduced neural plasticity; lost cortical inhibition.	Prolonged recovery, fixed bladder capacity, and multifactorial nocturia.
Symptomatic	Severe Baseline Storage Sub-score	Established autonomous vesicle hyperactivity; advanced mechanoreceptor sensitization.	Refractory urgency and high postoperative OAB-v8 scores.
Urodynamic	Low Cystometric Capacity (<250 mL)	Severe interstitial fibrosis; inelastic collagen deposition; stiffened bladder matrix.	Persistent daytime frequency and reduced functional voided volumes.
Urodynamic	Low-Volume or Terminal DO	Severe myogenic disinhibition; denervation supersensitivity; structural loop breakdown.	Postoperative Urgency Urinary Incontinence (UUI) and catastrophic storage failure.
Urodynamic	Detrusor Underactivity (BCI<100)	Myocyte vacuolization; mitochondrial decay; chronic contractile decompensation.	Elevated PVR, overflow-induced frequency, and persistent poor stream.
Obstructive	Low Obstruction Index (BOOI<40)	Absence of mechanical impedance; misdiagnosed underlying bladder dysfunction.	Minimal symptomatic improvement; high risk of post-surgical regret.
Systemic	Metabolic Syndrome & Diabetes	Autonomic neuropathy; pelvic ischemia; pro-inflammatory cytokine expression.	Mixed sensory/ motor OAB; progressive storage failure; poor tissue healing.

Table 2: Structured preoperative assessment and diagnostic triage protocol.

Diagnostic Step	Target parameter / modality	Clinical rationale and thresholds	Actionable preoperative intervention / strategy
Symptom Quantification	IPSS Storage Sub-score & OAB-v8	Identify storage dominance; scores >12 indicate high risk of primary bladder disease [3,6].	Establish a baseline for tracking progress and explicitly counsel the patient on slower recovery.
Functional Assessment	3-Day Frequency-Volume Chart	Differentiate low functional capacity (<200 mL) from systemic nocturnal polyuria (>33%) [19].	Incorporate lifestyle modifications, optimize fluid intake timing, or refer for sleep/ cardiovascular workups.
Non-Invasive Diagnostics	Uroflowmetry & Ultrasound PVR	Verify voiding baseline; PVR>150 mL" suggests potential detrusor underactivity or severe obstruction [4,17].	Correlate with obstruction metrics to ensure the patient is an appropriate candidate for surgery.
Selective Urodynamics	Multi-channel Pressure-Flow Study	Indicated for: Age >75, PVR>200 mL" , low prostate volume with severe LUTS, or previous surgical failures [15].	Formally calculate the BOOI and BCI; confirm structural obstruction before proceeding with surgery [15,17].
Medical Comorbidity Screening	HbA1c, Lipids, Sleep History (STOP-BANG)	Identify underlying poorly controlled diabetes, metabolic syndrome, or signs of obstructive sleep apnea [21,22].	Coordinate care with endocrinology or cardiology to optimize systemic health prior to surgical intervention.

severe detrusor overactivity is confirmed, advanced third-line therapies should be considered, including intravesical injections of Botulinum Toxin A (100 units injected into the detrusor muscle, sparing the trigone) or the placement of a Sacral Neuromodulation (SNM) system to restore normal neural signaling loops [16].

Discussion and future Perspectives

The clinical insights synthesized in this narrative review highlight a fundamental shift in male functional urology from a prostate-centric approach to a more holistic, bladder-centric and systemic paradigm [1,2]. The finding that structural relief of obstruction does not immediately equate to symptom resolution underscores the role of chronic bladder tissue remodeling as a distinct, self-sustaining pathophysiological entity [7,10].

Future research must prioritize the identification of non-invasive biomarkers-such as urinary Nerve Growth Factor (NGF) or advanced bladder wall ultrasound elastography-capable of quantifying detrusor fibrosis and ischemia before surgical intervention [23]. Furthermore, prospective trials evaluating the early initiation of combination therapies (e.g., anti-inflammatory agents combined with neuromodulators) immediately following surgery are warranted to determine if the functional "memory" of the bladder can be re-programmed or reversed more efficiently [7,26].

Conclusions

Postoperative storage LUTS persistence reflects an established vesicle-centric or systemic phenotype rather than a surgical failure. Prostatic deobstructive surgery is highly effective at eliminating mechanical outlet impedance, but it cannot instantly reverse the ultra-structural, neurogenic, and ischemic damage sustained by the detrusor and urothelium over years of chronic hydrostatic overload. Preoperative phenotyping utilizing standardized symptom questionnaires, detailed 3-day bladder diaries, and selective multi-channel urodynamics is critical to manage patient expectations and design realistic, multidimensional postoperative care pathways.

References

1. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: A shift from prostate-centric to multi-organ management paradigms. BJU Int. 2018; 122(4): 532-541.
2. Roehrborn CG. Pathology of benign prostatic hyperplasia and its impact on bladder remodeling: An age-dependent process. Nat Rev Urol. 2020; 17(7): 395-408.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167-178.
4. Gravas S, Cornu JN, Gacci M, et al. EAU guidelines on management of non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Eur Urol Guidelines. 2022; 71(4): 450-463.
5. Choi H, Kim JH, Chang IH, et al. Predictors of persistent overactive bladder symptoms after transurethral resection of the prostate in patients with benign prostatic hyperplasia. Int Neurourol J. 2019; 23(2): 132-139.
6. Gacci M, Sebastianelli A, Salvi M, et al. Persistence of storage LUTS after deobstructive surgery for benign prostatic enlargement: A systematic review and meta-analysis. Eur Urol Focus. 2021; 7(5): 1102-1111.
7. Levin RM, Haugaard N, O'Connor L, et al. The bladder remembers: Structural and functional memory of the detrusor after long-standing hydrostatic overload. J Urol. 2017; 198(3): 512-520.
8. Greenwell TJ, Greenfield JM, O'Connor FC. Methodological approach to functional urology literature: Evaluating narrative vs systematic outcomes. World J Urol. 2021; 39(2): 331-339.
9. Mirone V, Imbimbo C, Longo N, et al. Detrusor smooth muscle cell hypertrophy and hyperplasia under chronic afterload: A genetic and structural pathway. Eur Urol. 2019; 75(4): 611-620.
10. Andersson KE. Bladder wall remodeling and extracellular matrix deposition in bladder outlet obstruction. Neurourol Urodyn. 2018; 37(4): 15-22.
11. Azadzoi KM, Tarcan T, Siroky MB, et al. Patchy denervation and afferent remodeling secondary to microvascular ischemia in the obstructed bladder. J Urol. 2016; 196(2): 589-597.
12. Brading AF. Ischemia-reperfusion injury and denervation supersensitivity in the overactive bladder infrastructure. Nat Clin Pract Urol. 2017; 4(11): 602-611.
13. Birder LA, Andersson KE. Urothelial signaling and mechanoreceptor alterations in lower urinary tract dysfunction. Physiol Rev. 2013; 93(2): 653-680.
14. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition and the sensory basis of overactive bladder. Nat Rev Neurosci. 2018; 19(6): 345-357.
15. Gharib AL, Shaker MA, Al-Kandari AM. Urodynamic predictors of persistent storage lower urinary tract symptoms after deobstructive prostate surgery. J Urol. 2021; 205(4): 1145-1152.
16. Gammie A, Clarkson B, Constantinou C, et al. International Consultation on Incontinence-Research Society (ICI-RS) consensus statement: Urodynamic profiles of detrusor overactivity and clinical resistance. Neurourol Urodyn. 2022; 41(6): 1289-1297.
17. Seki N, Nomura M, Yamaguchi A, et al. Long-term outcomes of storage symptoms after deobstructive surgery: Impact of baseline detrusor underactivity. BJU Int. 2020; 126(3): 384-391.
18. Cornu JN, d'Ancona C, Drake MJ, et al. Nocturia: A complex, multifactorial challenge resistant to local surgical deobstruction. Eur Urol. 2018; 74(5): 611-621.
19. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and management of nocturia: Consensus statement from the International Continence Society. Neurourol Urodyn. 2019; 38(2): 502-514.
20. Wittig K, Daneshgari F. Diabetic cystopathy: Pathophysiology and clinical correlates of storage dysfunction in the aging male. Nat Rev Urol. 2023; 20(5): 291-302.
21. Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus: From osmotic diuresis to neuropathy. Front Pharmacol. 2016; 7: 411.
22. Michel MC, Korstanje C. Metabolic syndrome, pelvic ischemia, and the hyperactive bladder: A systematic review of cross-sectional links. Eur Urol. 2022; 81(2): 167-175.
23. Steers WD, Tuttle JB. Neurotrophic factors and Nerve Growth Factor (NGF) expression in ischemia-induced bladder inflammation. 2019; 27(1): 45-52.
24. Reitz A, Haferkamp A, Schurch B. The ice water test nomogram: Predicting persistent storage symptoms post-TURP utilizing intrinsic bladder reflexes. World J Urol. 2018; 36(9): 1443-1450.
25. Loufopoulos I, Radopoulos D, Anastasiadis A. Comprehensive predictive tools and multi-variable models for post-deobstructive storage symptoms: A systematic review. Neurourol Urodyn. 2024; 43(1): 12-25.
26. Chapple C, Kaplan SA, Mitcheson D, et al. Targeted pharmacotherapy for post-deobstructive storage LUTS: Mirabegron versus antimuscarinics. Int J Clin Pract. 2021; 75(8): 14302.